Fig. 6: Assessments of IL biocompatibility and toxicity to canines upon p.o. administration.
a Schematic illustration of the experimental design for p.o. administration of PBS (Conn), C3MIMCl (C3), or C12MIMCl (C12) to dogs (beagles) and corresponding analysis. b Table summarizing the occurrence of emesis, diarrhea, hematochezia, and listlessness of the dogs after the p.o. administration of PBS or ILs. c Relative serum Na+ and Cl− levels of dogs after 24 h of different treatments. Data were normalized to the levels of the untreated dogs. d H&E staining images of the stomachs and intestines of dogs receiving different treatments. e Routine blood test for the relative Mon% and Lym% of dogs after 24 h of different treatments. Data were normalized to the levels of the untreated dogs. f Urea and Scr levels of dogs after 24 h of different treatments. g Plasma concentration-time curves of insoluble drug (megestrol acetate) under two conditions: commercial tablet or C3MIMCl formulation following p.o. administration at 40 mg. h Pharmacokinetic analysis of systemic exposure (AUC0-inf) and peak concentration (Cmax) following p.o. administration of megestrol acetate. AUC0-inf is estimated by computing the integral of the concentration-time curve from time zero to infinity. Cmax is recorded as the maximum observed drug concentration. Data in (c, e–g) and (h) represent the mean ± s.e.m., n = 3 biologically independent dogs per group. Statistical significance was calculated via one-way ANOVA (c, e) or two-tailed Student’s t test (f, g, h). Source data were provided as a Source Data file.
